Iain Webb’s Post

The UK Biobank is a fantastic resource, carefully designed, with in-depth genetic data and health information on 0.5 million participants and long-term follow-up. Facilitating access to the UK Biobank database to researchers from LMICs will help them: 1. Improve their research capacity. I see more students gaining access to this resource for either training purposes or their degree programs. This will, at least, transform how epidemiology and medical statistics is being taught. 2. Continue contributing to high-quality global health research, tackling some of the most pressing global health challenges. 3. Build international collaborations with researchers from other countries. These benefits would: 1. Bridge the current research gap between high-income countries and LMICs. 2. Facilitate access to global research opportunities. 3. Improve economic benefit via increased ability to compete from research grants.

Looking for company NOMINATIONS for Biotech Week Boston Awards! Submission Deadline Extended to Friday, May 10. I am honored to be a judge again this year. The BWB Awards at Biotech Week Boston is a celebratory gala of networking, food, drink, and entertainment on September 23rd in Boston. The 2024 Award Categories Are: • START-UP OF THE YEAR - The Start-up of the Year award recognizes a burgeoning company that has blossomed into an industry leader through growth and innovation. Sponsored by Stratacuity. • DE&I INITIATIVE - The DE&I Initiative award recognizes an organization or group that has advanced diversity, equity, and inclusion in the workplace by championing the perspectives and contributions of employees representing marginalized groups. • BIOTECH INNOVATION – The Biotech Innovation award recognizes a company or organization that has conceived a new or advancing biopharmaceutical product, manufacturing process or ground-breaking technology that yielded significant results. • DEAL OF THE YEAR - The Deal of the Year award recognizes the companies and individuals involved in forming a transformative business partnership, such as a major drug-licensing agreement or a successful merger/acquisition deal between companies. • TALENT ACCELERATION - The Talent Acceleration award recognizes an organization that has shown exceptional aptitude for training workers to develop the skills they need to thrive in the rapidly growing biopharmaceutical industry. • SUSTAINABILITY INITIATIVE - The Sustainability Initiative award recognizes the company that best embodies the spirit of sustainability through a conscious effort to improve its environmental impact through policy, training, and innovation. • CLINICAL ADVANCE OF THE YEAR - The Clinical Advance of the Year award recognizes an emerging drug that has passed through clinical trials and is expected to have a ground-breaking impact on healthcare in the years to come. • LIFETIME ACHIEVEMENT AWARD - The Lifetime Achievement award recognizes an exceptional individual who has served the industry beyond the call of duty throughout a distinguished career. • BOSTON HIGHLIGHT - The Boston Highlight award recognizes a standout life-sciences organization or person based in the Boston area that has made a significant contribution to the biopharmaceutical industry over the past year. • TRANSFORMATIONAL THERAPY - The Transformational Therapy award recognizes innovation in the discovery, development, delivery, and/or market accessibility of an advanced-therapy drug product that is designed to treat rare diseases with currently unmet medical needs. https://lnkd.in/e68bdtcQ

🌐 #RAREis Global Advocate Grant 2024 🗓 Deadline: May 31, 2024 Amgen’s #RAREis Global Advocate Grant is now accepting applications. This initiative aims to support and empower individuals and communities affected by rare diseases worldwide. To qualify for consideration, an organization must be considered a non-profit organization, focused on supporting the rare disease community outside of Amgen’s disease states, all funds will be used in the year received and no healthcare providers will be receiving benefit from this grant. Past grant awardees are eligible to reapply and receive repeat funding. For more details on how to apply, visit 2024 #RAREis Global Advocate Grant (rareiscommunity.com) #WeareBiotech #CommunitySupport #RareDiseases #GlobalAdvocacy #Empowerment #Grant

How can individual countries take action to help rebuild the antimicrobial pipeline, ensure sustainable access to these drugs and help stop the growth of AMR? Our latest policy brief (available in English and Danish) outlines actions that could be taken by Denmark to support innovation and access to antimicrobials through creating pull incentives and demonstrates that these policies would give a strong Return on Investment. Our key messages include: 🔸 Even within Denmark, a small country with a relatively low AMR burden, there are nearly 500 deaths directly attributable to AMR each year and another 2,000 deaths associated with AMR. 🔸Based on our modelling (adapted from the excellent work of the Center for Global Development) we estimate that implementing a pull incentive scheme to incentivise the development of 18 new drugs over 30 years would: 🔹 Save 350 lives over 10 years with an ROI of 3.5:1 and 6,700 lives over 30 years with an ROI of 16.5:1 when considering all drug-pathogen combinations.  🔹 Save 250 lives over 10 years with an ROI of 2.5:1 and 4,800 lives over 30 years with an ROI of 11.8:1 when considering the 6 top pathogens. 🔸Denmark has an opportunity to use the ongoing update to its National Action Plan on AMR to include commitments to pull incentive policies and should consider investigating how a pull incentive scheme could be operated within a Danish context and as part of an EU scheme, ideally leading to a pilot program in the coming years. The time for action to support antimicrobial developers and ensure patients have access to the drugs they need to treat increasingly common drug resistant infections is now and we believe that these actions can play an important role in driving this forward. https://lnkd.in/eUxbpA2U

How can individual countries take action to help rebuild the antimicrobial pipeline, ensure sustainable access to these drugs and help stop the growth of AMR? Our latest policy brief (available in English and Danish) outlines actions that could be taken by Denmark to support innovation and access to antimicrobials through creating pull incentives and demonstrates that these policies would give a strong Return on Investment. Our key messages include: 🔸 Even within Denmark, a small country with a relatively low AMR burden, there are nearly 500 deaths directly attributable to AMR each year and another 2,000 deaths associated with AMR. 🔸Based on our modelling (adapted from the excellent work of the Center for Global Development) we estimate that implementing a pull incentive scheme to incentivise the development of 18 new drugs over 30 years would: 🔹 Save 350 lives over 10 years with an ROI of 3.5:1 and 6,700 lives over 30 years with an ROI of 16.5:1 when considering all drug-pathogen combinations.  🔹 Save 250 lives over 10 years with an ROI of 2.5:1 and 4,800 lives over 30 years with an ROI of 11.8:1 when considering the 6 top pathogens. 🔸Denmark has an opportunity to use the ongoing update to its National Action Plan on AMR to include commitments to pull incentive policies and should consider investigating how a pull incentive scheme could be operated within a Danish context and as part of an EU scheme, ideally leading to a pilot program in the coming years. The time for action to support antimicrobial developers and ensure patients have access to the drugs they need to treat increasingly common drug resistant infections is now and we believe that these actions can play an important role in driving this forward. https://lnkd.in/eUxbpA2U

DONATE TO THE MSA DRUG REPURPOSING EXPLORATORY FUND: www.defeatmsa.org/donate ~ Choose the MSA Drug Repurposing Fund - Thank You for the Donation! #defeatmsa #kickmsa #msawarriors #newdrugs #clinical #msaresearch #clinicalresearch #repurposing #drugs ~ About the Cure Parkinson’s UK iLCT Program, a pioneering drug repurposing program for Parkinson’s - explained by Dr Patrik Brundin: https://lnkd.in/gMW86-7f

A year in review. In the first year of the DYNC1H1 Association we.... - Engaged & Networked with 47 Researchers - Had 133 patients from 28 countries join our Patient Contact Registry and nearly tripled the Simons Searchlight numbers for DYNC1H1.  - Raised over $45,000 dollars for treatments for DYNC1H1 Related Disorders. - Held almost 80 meetings with families, Biotech companies, pharmaceutical companies, researchers, and other patient advocacy groups who share our vision of a DYNC1H1 diagnosis coming with hope. In Year 2, we need your help to continue this fight.  Consider hosting a fundraiser on Social Media, donating, sharing, and volunteering with us. For more information visit www.dync1h1.org/volunteer Researchers, clinicians, and biotech: Join us at https://lnkd.in/ec2HzXnG Together we can find a safe, effective treatment. #dync1h1 #raredisease #smaled #cmt2o #epilepsy #DrugRepurposing #GeneTherapies #HopeForRare

We're not "wishing and hoping" that plant-based cannabis molecules will fight the disease when we know that our natural internal cannabis molecules perform the same actions. Because there are similar compounds, namely phytocannabinoids, that effect the same system, the endocannabinoid system, we've deemed them as "cannabimimetic." Our #501c3nonprofit #donates #hempproducts #cancerpatients #qualityoflife #casestudies #like #follow #share #subscribe #donate #GotCancer #Apply #ApplyOnline #hempitforward.org

For anyone that has suffered from pushing the document and data regulatory boulder uphill, only to have to do it again the next day, same path, same grind, crying out in your head (because to do so at work would get you a visit from HR) "please, God!! There has GOT to be a better way than this!!" What's great about Accumulus Synergy: It's not regulatory operations business as usual. It's a creative, strategic, collaborative solution to the crushing boot of inefficiency in the typical regulatory process. Bravo and best of luck! This is clearly a space where creative innovation is needed.

Moving forward the transformation of the regulatory filing process globally